Back أوباداسيتينيب Arabic Upadacitinib Spanish Upadacitinib French אופדסיטיניב HE ウパダシチニブ Japanese ଉପାଡାସିଟିନିବ OR

Upadacitinib

Upadacitinib
Clinical data
Pronunciation/juˌpædəˈsaɪtɪnɪb/
ew-PAD-ə-SY-ti-nib
Trade namesRinvoq
Other namesABT-494
AHFS/Drugs.comMonograph
MedlinePlusa619051
License data
Pregnancy
category
  • AU: D
  • Not recommended[1]
Routes of
administration		By mouth
Drug classJanus kinase (JAK) inhibitor
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding52%
MetabolismLiver (CYP3A major, CYP2D6 minor)[13]
MetabolitesM4, an acyl glucuronide
Elimination half-life9–14[12] (6–15[13]) hours
ExcretionMainly unchanged in feces (38%) and urine (24%)[12]
Identifiers
  • (3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC17H19F3N6O
Molar mass380.375 g·mol−1
3D model (JSmol)
  • CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
  • InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1 checkY
  • Key:WYQFJHHDOKWSHR-MNOVXSKESA-N checkY

Upadacitinib, sold under the brand name Rinvoq, is a medication used for the treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and axial spondyloarthritis.[10][11] Upadacitinib is a Janus kinase (JAK) inhibitor that works by blocking the action of enzymes called Janus kinases.[10][14][11] These enzymes are involved in setting up processes that lead to inflammation, and blocking their effect brings inflammation in the joints under control.[11]

Common side effects include upper respiratory tract infections (common cold, sinus infections), nausea, cough, and fever.[10][11]

Upadacitinib was approved for medical use in both the United States and the European Union in 2019.[11][14][15][16]

  1. ^ "Upadacitinib (Rinvoq) Use During Pregnancy". Drugs.com. 23 September 2019. Archived from the original on 18 March 2020. Retrieved 17 March 2020.
  2. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
  3. ^ "AusPAR: Upadacitinib". Therapeutic Goods Administration (TGA). 25 August 2021. Archived from the original on 4 September 2021. Retrieved 4 September 2021.
  4. ^ "Rinvoq (Abbvie Pty Ltd)". Archived from the original on 9 November 2022. Retrieved 9 November 2022.
  5. ^ "Rinvoq (Abbvie Pty Ltd)". Therapeutic Goods Administration (TGA). 16 February 2023. Archived from the original on 18 March 2023. Retrieved 9 April 2023.
  6. ^ "Rinvoq Product information". Health Canada. 25 April 2012. Archived from the original on 30 May 2022. Retrieved 29 May 2022.
  7. ^ "Summary Basis of Decision (SBD) for Rinvoq". Health Canada. 23 October 2014. Archived from the original on 31 May 2022. Retrieved 29 May 2022.
  8. ^ "Regulatory Decision Summary for Rinvoq". Drug and Health Products Portal. 21 July 2023. Retrieved 1 April 2024.
  9. ^ "Rinvoq 15 mg prolonged-release tablets - Summary of Product Characteristics (SmPC)". (emc). 1 March 2020. Archived from the original on 27 August 2021. Retrieved 22 August 2020.
  10. ^ a b c d Cite error: The named reference Rinvoq FDA label was invoked but never defined (see the help page).
  11. ^ a b c d e f "Rinvoq EPAR". European Medicines Agency (EMA). 16 October 2019. Archived from the original on 20 October 2020. Retrieved 29 April 2020.
  12. ^ a b Cite error: The named reference AssessmentReport was invoked but never defined (see the help page).
  13. ^ a b Mohamed MF, Camp HS, Jiang P, Padley RJ, Asatryan A, Othman AA (December 2016). "Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Participants with Rheumatoid Arthritis". Clinical Pharmacokinetics. 55 (12): 1547–1558. doi:10.1007/s40262-016-0419-y. PMID 27272171. S2CID 39036534.
  14. ^ a b "Drug Trials Snapshots: Rinvoq". U.S. Food and Drug Administration (FDA). 16 August 2019. Archived from the original on 5 August 2020. Retrieved 18 March 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  15. ^ Cite error: The named reference Drug Approval Package: Rinvoq was invoked but never defined (see the help page).
  16. ^ "AbbVie Receives FDA Approval of Rinvoq (upadacitinib), an Oral JAK Inhibitor for the Treatment of Moderate to Severe Rheumatoid Arthritis" (Press release). AbbVie. Archived from the original on 16 August 2019. Retrieved 16 August 2019.